Celtrix Pharmaceuticals, Inc.

Other

Joseph A Carlino

Larry Ellingsworth

Isia Bursuker

Bernice Schacter

Christopher A Maack

Howard R Higley

George Spitalny

Etty N Benveniste

Kim Neddermann

Naina Singh

TGF.beta. is used to increase the numbers of stem cells in a subject's peripheral blood. Then the subject's blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF.beta. administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.

Increase in hematopoietic progenitor cells in peripheral blood by

Methods for modulating the expression of inflammatory cytokines in the central nervous system comprising administering an effective amount of TGF-.beta. are disclosed. The methods include suppressing pro-inflammatory cytokines in the central nervous system by administering an effective amount of TGF-.beta. and inducing anti-inflammatory cytokines in the central nervous system by administering an effective amount of TGF-.beta..

Methods of modulating inflammatory cytokines in the CNS using TGF-.beta.

Indications associated with dysfunction or malfunction of hematopoiesis or lymphopoiesis are treated with a CIF (TGF-.beta.).

Inducing granulocyte production or B cell production in peripheral blood

This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.

Treatment of immunologic and hematologic disorders with IGFBP alone or

Treatment with Transforming Growth Factor-.beta. alone or in combination with a Colony Stimulating Factor therapeutically increases the number of granulocytes and monocyte/macrophages in mammals.

Growing community of inventors

San Leandro, CA, United States of America

Joseph A Carlino